VivoSeq
Oncology

Advanced Sarcoma

0

Pipeline Programs↗

8

Active Trials↗

4

Companies Involved↗

Advanced Sarcoma is an early-stage landscape with 0 programs across 4 companies. The most active players are Merck & Co., Eli Lilly, Essen Biotech.

Intelligence

Pipeline Metrics

Competitive Density

24/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

90/100

Attrition Rate

7/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Merck & Co. logo

Merck & Co.

0 programs

PreclinicalEli Lilly logo

Eli Lilly

0 programs

PreclinicalE

Essen Biotech

0 programs

PreclinicalA

Alaunos Therapeutics

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

29

clinical trials

Completed18 · 62%
Recruiting6 · 21%
Withdrawn2 · 7%
Active, not recruiting2 · 7%
Unknown status1 · 3%

Clinical Trials

Trial Activity

29 trials

Bintrafusp Alfa and Doxorubicin Hydrochloride in Treating Patients With Advanced Sarcoma
Recruiting·IInstitut Bergonié·Phase 2·NCT04874311·80 enrolled
MAGNATE-S: Paclitaxel Polymer Micelles Combo in Advanced Sarcoma
Recruiting·SShanghai 6th People's Hospital·Phase 2·NCT07359053·46 enrolled
GALLANT: Metronomic Gemcitabine, Doxorubicin, Docetaxel and Nivolumab for Advanced Sarcoma
Recruiting·SSarcoma Oncology Research Center, LLC·Phase 2·NCT04535713·260 enrolled
HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma
Recruiting·—·Phase 1·NCT04995003·25 enrolled
Combination of Pembrolizumab and Cabozantinib in Patients With Advanced Sarcomas
Recruiting·IInstitut Bergonié·Phase 2·NCT05182164·119 enrolled
Sequential Infusion of CD146-Targeted and HER2-Targeted CAR T Cells in Patients With Advanced Sarcomas
Recruiting·EEssen Biotech·Phase 1/2·NCT07066982·60 enrolled
APX005M and Doxorubicin in Advanced Sarcoma
Active, not recruiting·—·Phase 2·NCT03719430·27 enrolled
Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma
Active, not recruiting·—·Phase 1·NCT00902044·36 enrolled
Trial of Dasatinib in Advanced Sarcomas
Completed·SSarcoma Alliance for Research through Collaboration·Phase 2·NCT00464620·366 enrolled
Clinical Study of Metronomic Oral Cyclophosphamide in Patients With Advanced Sarcomas
Completed·National Cancer Centre, Singapore·Phase 2·NCT01716689·24 enrolled
Whole-Body Hyperthermia Plus Chemotherapy in Treating Patients With Advanced Sarcoma
Completed·UUniversity of Wisconsin, Madison·Phase 2·NCT00002974·34 enrolled
Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED)
Completed·Merck & Co. logoMerck & Co.·Phase 2·NCT00093080·216 enrolled
Trabectedin Plus Olaparib in Metastatic or Advanced Sarcomas (TOMAS)
Completed·IItalian Sarcoma Group·Phase 1·NCT02398058·50 enrolled
A Phase II Study of Oral Cyclophosphamide and Sirolimus (OCR) in Advanced Sarcoma
Completed·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT00743509·49 enrolled
A Five-Tier, Open-Label Study of IMC-A12 in Advanced Sarcoma
Completed·Eli Lilly logoEli Lilly·Phase 2·NCT00668148·113 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)